Therefore, in this study we investigate the effective combination of Herceptin (Trastuzumab, Genentech Inc, CA, USA) [23-25], targeting for HER-2/neu oncoprotein, with anti-cancer drugs in gastric cancer cell lines, depending on the HER-2/neu oncoprotein expression. Here, ERBB2 is linked to gastric cancer.